Royalty Pharma closes acquisition of RP LLC; $200M cash, shares, and $380M debt assumed

Royalty Pharma plc

Paid $200M cash plus 24,530,266 non-voting Class E shares; assumed RP Management's $380M term loan.
Share consideration to Pablo Legorreta vests over 5 years; other management members vest over 10 years.
Joinder of Royalty Pharma Holdings Ltd and RP LLC as borrowers under existing $380M term loan; RP Management released.
Amended exchange agreement allows recipients to exchange RPH non-voting shares for Royalty Pharma Class A shares.
Amended articles of association of Royalty Pharma plc and RPH to reflect new share classes and procedural refinements.

item 2.01 item 1.01 item 2.03 item 5.02 item 5.03 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.